Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | LDHB | P07195 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27673058 | 0.84 | NPC1 (0.50) | HSD11B1CES2CES1CNR2ADRB1 | |
| SCHEMBL18282961 | 0.80 | PPARG (0.44) | HSD11B1CES2CES1CNR2ADRB1 | |
| SCHEMBL22728190 | 0.75 | KDM4E (0.61) | HSD11B1CES2CES1ADRB1ADRB3 | |
| SCHEMBL18291969 | 0.75 | AOC3 (0.58) | HSD11B1CES2CES1CNR2FAAH | |
| SCHEMBL18741979 | 0.74 | CES2 (0.44) | HSD11B1CES2CES1CNR2ADRB1 | |
| SCHEMBL28540885 | 0.74 | ASAH1 (0.46) | HSD11B1CES2CES1CNR2NPC1 | |
| Hydrochloric Acid SCHEMBL18281298 | 0.73 | AOC3 (0.56) | HSD11B1CES2CES1CNR2FAAH | |
| SCHEMBL15110622 | 0.73 | FFAR1 (0.55) | SRD5A2PTPN1 | |
| SCHEMBL28333319 | 0.73 | FAAH (0.54) | HSD11B1CNR2FAAHACP3 | |
| SCHEMBL2762774 | 0.73 | HSD11B1 (0.46) | HSD11B1CES2CES1CNR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3302484-B1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10160762-B2 | 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-17 | — | — | US | disclosed |
| EP-3302484-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016196071-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160762-B2 | 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors | PDE12, PDE2A, PDE4D | HSD11B1 591/4885CES2 336/4885CES1 2105/4885 |
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE4D | HSD11B1 591/4885CES2 336/4885CES1 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.